Abstract:One of the most common causes of cancer mortality worldwide is hepatocellular carcinoma (HCC). Extracellular signal-regulated kinase (ERK1/2) pathway has been shown to play an important role in the development and progression of HCC. Here, we demonstrate that the immunosuppressive agent cyclosporin A (CsA) has the ability to increase the cellular growth in HCC (HepG2 cells) via activation of ERK1/2 signaling cascade. It was found that ERK1/2 phosphorylation induced by CsA was highly reduced in the presence of the reactive oxygen species (ROS) scavenger polyethylene glycol-superoxide dismutase (PEG-SOD). Furthermore, it was observed that inhibition of metalloproteinase activity using TAPI-2 prevents ERK1/2 activation by CsA. Moreover, a disintegrin and metalloproteinase domain 17 (ADAM-17) activity was found to be critical for ERK phosphorylation by CsA. In addition, CsA-induced ERK phosphorylation was highly reduced in the presence of either neutralizing anti-heparin-binding-epidermal growth factor (HB-EGF) antibody or UO126 (MEK inhibitor). By using the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478, it was found that EGFR is critical for ERK phosphorylation induced by CsA. Furthermore, CsA-induced cell proliferation was strongly reduced in the presence of either PEG-SOD or TAPI-2 or neutralizing anti-ADAM17 antibody or neutralizing anti-HB-EGF antibody or AG1478 or UO126. Collectively, these data demonstrate that CsA has the ability to activate ERK1/2 signaling cascade that could be translated into an increase in HepG2 cell proliferation. Furthermore, these data support the role of ROS, ADAM-17, and EGFR in ERK1/2 signaling activation and subsequent cell proliferation induced by CsA in HepG2 cells.

Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal.

Cyclophilin A: promising target in cancer therapy

Cyclophilin A Promotes Human Hepatocellular Carcinoma Cell Metastasis Via Regulation of Mmp3 and Mmp9

Epac1 is Involved in Cell Cycle Progression in Lung Cancer Through PKC and Cx43 Regulation

Cyclophilin J Is a Novel Peptidyl-Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma

Clinical significance of cyclophilin a expression in esophageal squamous cell carcinoma.

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance

Cyclophilin A (cypa) Induces Chemotaxis Independent of Its Peptidylprolyl Cis-Trans Isomerase Activity

Cyclophilin D: Guardian or Executioner for Tumor Cells?

Secreted cyclophilin A is non-genotoxic but acts as a tumor promoter

Cyclophilin A associates with and regulates the activity of ZAP70 in TCR/CD3-stimulated T cells

Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway

Biochemical Features of Recombinant Human Cyclophilin J

PCYT1A Suppresses Proliferation and Migration Via Inhibiting Mtorc1 Pathway in Lung Adenocarcinoma.

Cyclophilin A knockdown inhibits the proliferation and metastatic ability of AGS gastric cancer stem cells by downregulating CD147/STAT3/AKT/ERK and epithelial‐mesenchymal transition

CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis

Cyclosporine A Inhibits Breast Cancer Cell Growth By Downregulating The Expression Of Pyruvate Kinase Subtype M2

PDE4 and Epac1 Synergistically Promote Rectal Carcinoma Via the Camp Pathway.

Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer

Cyclophilin J limits linear ubiquitin signaling and controls colorectal cancer progression